The big headline with Pfizer is that it will have to deal with revenue declines from drugs facing patent expirations over the next few years. That's normal, since new drugs are given a time-limited ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. The pharma giant announced Monday that sigvotatug vedotin, the first new ADC to read out pivotal data following its ...

Continuing with ongoing trial that combines drug with Keytruda Plans to explore using the drug with other experimental treatments Shares fall 1% June 22 (Reuters) - Pfizer (PFE.N), opens new tab said ...

Nike’s latest hire isn’t a retail veteran or a company insider like CEO Elliott Hill. Rather, he comes from the pharmaceutical industry.

The Trump administration’s dramatic reworking of U.S. public-health agencies’ approach to vaccines is creating a difficult and unpredictable situation for drugmakers.

Matthew Herper covers medical innovation — both its promise and its perils. Pfizer said Monday that an experimental drug it hoped could replace a widely used chemotherapy in one of the most common ...

Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn’t be treated with surgery, dealing a setback to the closely watched ...

Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five months to forge, but not without undergoing some stress tests. The deal ...

Javelin Biotech today announced a landmark scientific publication, titled "Interconnected multi-microphysiological systems and PBPK modeling for predicting human pharmacokinetics”, in the ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an ...